{
    "clinical_study": {
        "@rank": "124469", 
        "arm_group": [
            {
                "arm_group_label": "Atorvastatin", 
                "arm_group_type": "Experimental", 
                "description": "atorvastatin\uff1a20 mg (every evening orally) for 8 weeks"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo:20 mg (every evening orally) for 8 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the clinic effects and security of oral administration of Atorvastatin on\n      chronic subdural hematoma (CSDH)."
        }, 
        "brief_title": "Effect and Safety Study of Atorvastatin to Treat Chronic Subdural Hematoma", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Subdural Hematoma", 
        "condition_browse": {
            "mesh_term": [
                "Hematoma", 
                "Hematoma, Subdural", 
                "Hematoma, Subdural, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Study design:\n\n      Multi-center, randomized, double-blind, placebo parallel controlled\n\n      Subjects:\n\n      Patients with chronic subdural hematoma (CSDH)\n\n      Sample size:\n\n      200, including an Atorvastatin-treated group of 100 patients and a control group of 100\n      subjects."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age \u2267 18 and \u226490 years old, male or female;\n\n          2. CT scan reveals supratentorial, unilateral or bilateral chronic subdural hematoma\n             (MRI scan is warranted if diagnosis is difficult);\n\n          3. Markwalder's Grading Scale and Glasgow Coma Scale (MGS-GCS)\uff1cGrade 3;\n\n          4. Attending physician makes a judgment that cerebral hernia would not occur and\n             surgical operation might not be performed in a short time. Conservative treatment is\n             adopted;\n\n          5. Patients have never undergo surgery on the hematoma\n\n          6. Patient fully understood the nature of the study, and voluntarily participates and\n             signs informed consent.\n\n        Exclusion Criteria:\n\n          1. Allergic to the statin or its ingredients\n\n          2. Cerebral herniation might occur at any time;\n\n          3. Hematoma leads to herniation and warrants surgical operation.\n\n          4. Hematoma caused by tumors, blood and other known comorbidities;\n\n          5. Abnormal liver function\n\n          6. Uncontrolled hepatitis and other liver diseases, as well as suffering from other\n             disease may interfere the study\n\n          7. Patients have been on oral Statin treatment for a long time.\n\n          8. Patients have been on oral Steroids treatment for a long time.\n\n          9. In the past a year, patients have been on anti-platelet or warfarin\n\n         10. Participate in clinical trials in the past four weeks;\n\n         11. Pregnant or breastfeeding\n\n         12. Failure of completing the trial by poor compliance;\n\n         13. For any reason, the researchers believe that the case is not suitable for inclusion."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02024373", 
            "org_study_id": "CSDH2013"
        }, 
        "intervention": [
            {
                "arm_group_label": "Atorvastatin", 
                "description": "20 mg (every evening orally) for 8 weeks", 
                "intervention_name": "Atorvastatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo", 
                "description": "20 mg (every evening orally) for 8 weeks", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Atorvastatin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "chronic subdural hematoma", 
            "Atorvastatin", 
            "oral administration therapy"
        ], 
        "lastchanged_date": "December 25, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing"
                    }, 
                    "name": "Beijing tiantan hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "jianghope@gmail.com", 
                    "last_name": "Rongcai Jiang, MD, PhD", 
                    "phone": "86-22-60814348"
                }, 
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China", 
                        "state": "Tianjin", 
                        "zip": "300052"
                    }, 
                    "name": "Tianjin Medical University General Hospital"
                }, 
                "investigator": {
                    "last_name": "Jianning Zhang, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "Peking union medical college hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "Chinese PLA General Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Changsha", 
                        "country": "China"
                    }, 
                    "name": "Xiangya hospital central southe university"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China"
                    }, 
                    "name": "Southwest hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China"
                    }, 
                    "name": "West china hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Haerbing", 
                        "country": "China"
                    }, 
                    "name": "First Affiliated Hospital of Harbin Medical University"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China"
                    }, 
                    "name": "The second Affiliated hospital of zhejiang university school of medicine"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jinan", 
                        "country": "China"
                    }, 
                    "name": "Qilu hospital of shandong university"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "Changzheng Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "Huashan hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Xian", 
                        "country": "China"
                    }, 
                    "name": "Xijing Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Xianggang", 
                        "country": "China"
                    }, 
                    "name": "Prince of Wales Hospital"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Multi-Center, Randomized, Placebo-Controlled, Double Blind Study of the Atorvastatin: Effect on Patients With Chronic Subdural Hematoma", 
        "overall_contact": {
            "email": "jianghope@gmail.com", 
            "last_name": "RongCai Jiang, MD, PhD", 
            "phone": "86-22-60814348"
        }, 
        "overall_official": {
            "affiliation": "Tianjin Medical University General Hospital", 
            "last_name": "Ning jian zhang, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary efficacy endpoint: hematoma reduced amount. Outcome Measures: all patients underwent head CT (plain scan) before treatment, and check on 8 weeks during treatment (at the end)", 
            "measure": "Hematoma Reduced Amount.", 
            "safety_issue": "No", 
            "time_frame": "Check on  8 weeks during treatment (at the end)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02024373"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The consciousness score (MGS-GCS) and outcome score (GOS, ADL-BI Scale) in subjects", 
                "safety_issue": "No", 
                "time_frame": "0\uff0c7days\uff0c4, 8weeks during treatment (at the end), in the follow-up in 3 and 6 months."
            }, 
            {
                "measure": "Changes of neurological symptoms and signs", 
                "safety_issue": "No", 
                "time_frame": "0\uff0c7days\uff0c4, 8weeks during treatment (at the end), in the follow-up in 3 and 6 months."
            }, 
            {
                "measure": "Changes of routine blood test and coagulation results", 
                "safety_issue": "No", 
                "time_frame": "0\uff0c7days\uff0c4, 8weeks during treatment (at the end), in the follow-up in 3 and 6 months."
            }
        ], 
        "source": "Oriental Neurosurgery Evidence-Based-Study Team", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Oriental Neurosurgery Evidence-Based-Study Team", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}